These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1233 related articles for article (PubMed ID: 19509327)

  • 21. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 26. Malignancy and biologic therapy in rheumatoid arthritis.
    Askling J; Bongartz T
    Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety overview of new disease-modifying antirheumatic drugs.
    Cush JJ
    Rheum Dis Clin North Am; 2004 May; 30(2):237-55, v. PubMed ID: 15172038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF therapy: safety aspects of taking the risk.
    Rosenblum H; Amital H
    Autoimmun Rev; 2011 Jul; 10(9):563-8. PubMed ID: 21570495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics in early rheumatoid arthritis.
    de Vries-Bouwstra JK; Dijkmans BA; Breedveld FC
    Rheum Dis Clin North Am; 2005 Nov; 31(4):745-62. PubMed ID: 16287595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of biologic therapies--an update.
    Keystone EC
    J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell agents in the treatment of rheumatoid arthritis.
    Solomon GE
    Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.
    Favalli EG; Pregnolato F; Biggioggero M; Meroni PL
    Semin Arthritis Rheum; 2014 Jun; 43(6):730-7. PubMed ID: 24332807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.